HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

OICR-9429

antineoplastic; structure in first source

Also Known As:

N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-(1,1'-biphenyl)-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

Networked: 8 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        OICR-9429: 8
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - OICR-9429: 8

Experts

1.	Chen, Xu: 1 article (06/2021)
2.	Chen, Yuelong: 1 article (06/2021)
3.	Cheng, Liang: 1 article (06/2021)
4.	Dong, Wen: 1 article (06/2021)
5.	Han, Jinli: 1 article (06/2021)
6.	Huang, Jian: 1 article (06/2021)
7.	Huang, Ming: 1 article (06/2021)
8.	Lin, Tianxin: 1 article (06/2021)
9.	Liu, Lixuan: 1 article (06/2021)
10.	Peng, Shengmeng: 1 article (06/2021)

Related Diseases

1.	Neoplasms (Cancer) 11/27/2023 - "Application of a small chemical inhibitor for MLL1 activity, OICR-9429, represses target gene expression of the identified Vm3Es, enhances anti-tumor immunity and inhibits CRC growth in an animal model. " 01/01/2019 - "Treatment with OICR-9429, a small-molecule antagonist of the WDR5-MLL interaction, inhibits the β-catenin/JDP2/PRMT5 complex-reestablished GSH metabolism, leading to a lethal increase in the already-elevated levels of ROS in the genotoxic-agent treated cancer cells. " 06/20/2018 - "OICR-9429 treatment was particularly toxic to SW620 and T84 colon cancer cells, two cell lines without mutations in WDR5 and KMT2/MLL proteins suggesting COMPASS complex inhibition may be particularly effective in tumors lacking KMT2 mutations. " 01/01/2018 - "Several small molecule MLL/WDR5 protein-protein interaction inhibitors, such as MM-401, MM-589, WDR5-0103, Piribedil, and OICR-9429, have been confirmed to reduce H3K4 trimethylation, oncogenic gene expression, cell cycle progression, cancer cell proliferation, survival and resistance to chemotherapy without general toxicity to normal cells. "
2.	Colonic Neoplasms (Colon Cancer) 06/20/2018 - "WDR5 depletion reduced H3K4Me3 and increased phosphorylation of H2AX in HCT116, SW620, and RKO colon cancer cells; however, OICR-9429 treatment did not recapitulate these effects in all cell lines potentially explaining the reduced toxicity of OICR-9429 treatment as compared to WDR5 depletion. " 06/20/2018 - "OICR-9429 treatment was particularly toxic to SW620 and T84 colon cancer cells, two cell lines without mutations in WDR5 and KMT2/MLL proteins suggesting COMPASS complex inhibition may be particularly effective in tumors lacking KMT2 mutations. "
3.	Urinary Bladder Neoplasms (Bladder Cancer) 06/21/2021 - "This study evaluated the role of targeting WD repeat domain 5 (WDR5) with the small molecule compound OICR-9429 and whether it could be used to treat bladder cancer. "
4.	Reperfusion Injury 11/01/2019 - "MM-102 or OICR-9429, both MLL1/WDR5 protein-protein interaction inhibitors, and small interfering RNA (siRNA) for MLL1 or WDR5 suppressed the expression of p16INK4a in mice with ischemia reperfusion injury, accompanied by downregulation of H3K4me3 expression. "
5.	Neuroblastoma 04/01/2023 - "Most interestingly, we established the particularly high synergy rate by combining WBM site inhibitor 19 and the WIN site inhibitor OICR-9429, providing a novel therapeutic avenue for neuroblastoma."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	histone H3 trimethyl Lys4
3.	Aurora Kinase A
4.	Catenins
5.	Small Interfering RNA (siRNA)
6.	Piribedil (Trivastal)
7.	Cisplatin (Platino)
8.	Temozolomide (Temodar)
9.	MM-401
10.	MM-589

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)